Emmanuel Antonarakis, MD

Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:z-AlphaDate added:Date updated:11/09/2023Relationship end date:02/03/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Propella TherapeuticsDate added:Date updated:11/09/2023Relationship end date:08/04/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:PfizerDate added:Date updated:11/09/2023Relationship end date:02/01/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:OrionDate added:Date updated:11/09/2023
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:MerckDate added:Date updated:11/09/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Menarini Silicon BiosystemsDate added:Date updated:11/09/2023Relationship end date:11/30/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Hookipa PharmaDate added:Date updated:11/09/2023Relationship end date:10/14/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Foundation MedicineDate added:Date updated:11/09/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Corcept TherapeuticsDate added:Date updated:11/09/2023Relationship end date:03/01/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:Constellation PharmaDate added:Date updated:11/09/2023Relationship end date:05/01/2023